Gujarat Themis Biosyn Limited (GTBL) has filed a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding the initiation of material litigation proceedings.
The company has initiated arbitration proceedings against Optimus Drugs Private Limited (Optimus Drugs) before a Learned Sole Arbitrator. The dispute arises from Optimus Drugs' termination of a supply agreement contrary to the agreed terms.
The company, as claimant, is seeking the following financial claims:
- ₹75,00,00,000 (Seventy-Five Crore Rupees) towards Break Fees for breach of mandatory "Take-or-Pay" minimum purchase obligations
- ₹23,80,849 (Twenty-Three Lakh Eighty Thousand Eight Hundred Forty-Nine Rupees) towards interest on delayed payments, with further interest till actual payment
- ₹15,00,00,000 (Fifteen Crore Rupees) towards damages and financial losses
- Costs and other relief as deemed fit by the Hon'ble Tribunal
Total Claim Amount: ₹90,23,80,849 (Ninety Crore Twenty-Three Lakh Eighty Thousand Eight Hundred Forty-Nine Rupees)
The company has stated that it does not expect any financial implications due to penalty or compensation, as it is the claimant seeking recovery and damages in this proceeding.
The disclosure was signed by Vineet Gawankar, Company Secretary & Compliance Officer of Gujarat Themis Biosyn Limited, on June 26, 2026.